11月14日 - ** 药物开发商 Septerna SEPN.O股价盘前上涨 ~2%，报 19.55 美元
** 富国银行将其股票评级从 "等权重 "上调至 "增持"，目标价从18美元上调至28美元
** 券商称对该公司 SEP-479 的(口服 PTH1R) 安全性以及与该公司之前项目的差异化有信心
** 券商称，SEPN在犬科猴（cynomolgus monkeys）上进行的研究(cyno study) 将证明SEP-479与之前的药物SEP-786相比不存在胆红素问题，SEP-786显示胆红素水平升高。
** 富国银行称，该公司SEP-631化合物的第一阶段研究结果将成为近期的重要催化剂，同时SEP-479化合物也将于2026年底上市
** 截至上次收盘，该公司股价累计下跌约 16
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.